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Exosomes derived from embryonal 
and alveolar rhabdomyosarcoma 
carry differential miRNA cargo 
and promote invasion of recipient 
fibroblasts
Sandra E. Ghayad1, Ghina Rammal1,2, Farah Ghamloush2, Hussein Basma2, Rihab Nasr3, 
Mona Diab-Assaf4, Claude Chelala5 & Raya Saab2,3
Rhabdomyosarcoma (RMS) is an aggressive childhood soft tissue tumor, which exists in oncoprotein 
PAX-FOXO1 fusion positive and fusion negative subtypes, with the fusion-positive RMS being 
characterized by a more aggressive clinical behavior. Exosomes are small membranous vesicles secreted 
into body fluids by multiple cell types, including tumor cells, and have been implicated in metastatic 
progression through paracrine signaling. We characterized exosomes secreted by a panel of 5 RMS 
cell lines. Expression array analysis showed that, for both fusion-positive and fusion-negative cells, 
exosome miRNA clustered well together and to a higher extent than cellular miRNA. While enriched 
miRNA in exosomes of fusion-negative RMS cells were distinct from those of fusion-positive RMS cells, 
the most significant predicted disease and functions in both groups were related to processes relevant 
to cancer and tissue remodelling. Functionally, we found that RMS-derived exosomes exerted a positive 
effect on cellular proliferation of recipient RMS cells and fibroblasts, induced cellular migration and 
invasion of fibroblasts, and promoted angiogenesis. These findings show that RMS-derived exosomes 
enhance invasive properties of recipient cells, and that exosome content of fusion-positive RMS is 
different than that of fusion-negative RMS, possibly contributing to the different metastatic propensity 
of the two subtypes.
Rhabdomyosarcoma (RMS) is an aggressive childhood soft tissue tumor thought to arise from primitive mes-
enchymal cells with evidence of myogenic differentiation (reviewed in ref. 1). RMS occurs as two main histo-
logic subtypes: alveolar (ARMS) and embryonal (ERMS) histologies. The alveolar subtype is characterized, in the 
majority of cases, by a chromosomal translocation t(2;13) (q35;q14), resulting in the fusion of the gene encoding 
the DNA binding domain of Paired Box 3 (PAX3) with the gene encoding the transcriptional activation domain 
of Forkhead Box O1 (FOXO1, previously known as FKHR) on chromosome 13 (reviewed in ref. 1). An alternate 
chromosomal translocation t(1;13) (p36;q14) results in a fusion between PAX7 on chromosome 1 and FOXO1, 
and occurs in a minor proportion of ARMS (reviewed in ref. 2). These ARMS-specific translocations result in an 
oncogenic PAX3-FOXO1 or PAX7-FOXO1 fusion protein, respectively, which contribute to the aggressive and 
metastatic behavior of ARMS (reviewed in ref. 2). Indeed, ARMS tumors are metastatic at diagnosis in approxi-
mately 80% of patients, as compared to only 20% in ERMS, and are associated with poor outcome despite current 
multimodality therapy. Recently, it has been suggested that fusion status may be a better stratification marker than 
histology, and classification of RMS into fusion-positive versus fusion-negative (rather than ARMS and ERMS, 
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respectively) may be more useful in prognostication and clinical allocation of therapy3. Better understanding of 
the mechanisms by which both subtypes of RMS develop metastatic properties are needed, for development of 
novel therapies and improvements in outcome of patients with advanced disease4.
Exosomes are small secreted membrane-bound particles measuring 30 to 120 nm in diameter, that have 
been shown to play important roles in cell-cell signaling and cellular communication, promoting secretion of 
growth factors, cytokines, and angiogenic factors by stromal cells, proliferation of endothelial cells, and metastasis 
Figure 1. Characterization of exosomes derived from RMS cells. (a) Representative SEM micrographs of 
exosomes purified from the respective ERMS and ARMS cells. Histograms represent percentage of extracellular 
vesicles per diameter range. (b) Western blot for the indicated proteins in exosome “E” and respective cell “C” 
lysates, as indicated, for each of the RMS cell lines. (c) Histogram representing the average total exosome proteins 
(μ g) quantified by Bradford assay per 1 million cells. Bars represent standard deviation. (d) Representative 
confocal microscopy images (single z-slices) for GFP-transduced MEFs (green) after 2 hours of treatment with 
PKH 26-labeled exosomes (red) derived from JR1 cells. Images are representative of 2 independent experiments.
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Figure 2. miRNA profiling of RMS exosomes compared to donor cells. (a) Representative RNA quality 
verification using the Experion electrophoresis system showing the presence of 18 S and 28 S rRNA subunits 
in total RNA in cells “C” and RNA in exosomes “E” compared to the ladder “L”. Numbers over peaks and 
next to ladder bands refer to nucleotide size. (b) Hierarchical clustering of all deregulated miRNA probe sets 
in ERMS (n = 2) and ARMS (n = 3) exosomes compared to their respective donor cells in independent cell 
cultures. Each column represents a cell line replicate, and each row represents a miRNA. The scaled expression 
of each miRNA, denoted as the row Z-score, is plotted in green–red colour scale. High expression levels are 
indicated in green and low expression levels are shown in red. (c–e) Venn diagram of all commonly deregulated 
(enriched and depleted) miRNA in exosomes derived from (c) the 3 ERMS cell lines; (d) the 2 ARMS cell lines 
and (e), all 4 specified cell lines excluding Rh36. (f–h) Venn diagram of only commonly enriched miRNA in 
exosomes derived from (f), the 3 ERMS cell lines; (g) the 2 ARMS cell lines; and (h) all 4 specified cell lines 
excluding Rh36. (i) Validation by qRT-PCR of the enrichment of the specified miRNA in exosomes derived 
from the specified RMS cells. The small RNA RNU6 was used as endogenous control. Histograms represent the 
mean log-fold change of miRNA in exosomes relative to respective donor cells, from at least two independent 
experiments each performed in triplicate. Bars represent standard deviation. (j) Western blot for the indicated 
target proteins in lysates of BJ cells after treatment with 1X and 10X JR1- or Rh41-derived exosomes for 
48 hours, as specified, compared to the control exosome-free media ‘EF’.
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(reviewed in ref. 5). Upon endocytosis, exosomes deliver their active components, including proteins, RNA and 
miRNA directly into the cytoplasm of recipient cells, and can influence their biological processes6. Emerging 
evidence indicates that packaging of miRNA into exosomes is not random and may rely on sequence-specific and 
secondary structure7,8. Exosomes derived from cancer cells have been demonstrated to promote angiogenesis, 
invasion, migration and proliferation in recipient cells to support tumor growth9. Some of the most compelling 
studies for an important role of exosomes are in the highly metastatic tumor melanoma, where transfer of protein 
via exosomes was shown to be responsible for preparing the metastatic niche in multiple organs, thus facilitating 
melanoma metastasis10. In pediatric cancers, few studies have investigated the role of exosomes in tumor biology. 
Studies reported that Ewing sarcoma, medulloblastoma, and neuroblastoma cell lines secrete exosomes, with 
specific identifiable cargo11–13.
RMS is a particularly interesting tumor where paracrine signaling is likely important, specifically the 
fusion-positive subtype, which is known to be highly metastatic. We hypothesized that RMS-derived exosomes 
enhance invasiveness of RMS cells and associated fibroblasts via paracrine signaling, thus contributing to the 
known metastatic behavior of this aggressive tumor.
Results
RMS cells secrete detectable amounts of exosomes. We evaluated a panel of 5 well-characterized 
RMS cell lines for exosome secretion. All tested cell lines of both fusion-negative (and embryonal histology) 
RMS, namely the JR1, RD and Rh36 cell lines, and the fusion-positive (and alveolar histology) Rh30 and Rh41 
cell lines, were found to secrete small vesicles visualized using scanning electron microscopy (Fig. 1a, upper 
panel). Measurement of the isolated vesicles diameter confirmed a size range of 40–120 nm (Fig. 1a, lower panel), 
consistent with exosomes5. The identity of these vesicles as exosomes was confirmed by analysis of their protein 
cargo, as western blotting showed that they contained the exosome protein markers TSG101, HSC70 and GAPDH 
(Fig. 1b)14, and were devoid of Calnexin (Fig. 1b), a cellular protein that is localized to the endoplasmic reticu-
lum and therefore excluded from exosomes15. Notably, the fusion oncoprotein PAX3-FOXO1 was not present in 
exosomes derived from the fusion-positive RMS cell lines Rh30 and Rh41, despite being clearly present in the 
corresponding cell lysates (Fig. 1b). Exosomes collected at 72 hours of culture contained an average of 5 micro-
grams of protein per million cells, which was relatively uniform across all examined cell lines (Fig. 1c). To eval-
uate whether RMS-derived exosomes are indeed taken up by recipient cells, we used fibroblasts transduced with 
retrovirus expressing green fluorescent protein (GFP), and treated them with RMS-derived exosomes stained red 
with the PKH26 membrane dye. Confocal imaging showed that PKH26-stained exosomes were indeed taken up 
by cultured fibroblasts, clearly evident by 2 hours after exposure (Fig. 1d). We conclude that RMS cells secrete 
exosomes that can be readily isolated, and that these exosomes are taken up by recipient cells.
Category p-valuea Identified miRNA
Cancer 3.4 × 10−7–4.7 × 10−2 miR-1268, mir-548, miR-595, miR-1915-3p, mir-1915, miR-320b,  mir-550, miR-195-3p, miR-1207-5p, miR-638, miR-1228-5p
Organismal Injury and Abnormalities 3.4 × 10−7–4.7 × 10−2 miR-1268, miR-1908-5p, mir-548, miR-595, miR-1915-3p, mir-1915, mir-550, miR-320b, miR-195-3p, miR-1207-5p, miR-638, miR-1228-5p
Reproductive System Disease 3.4 × 10−7–2.3 × 10−2 miR-1268, mir-548, miR-1915-3p, mir-1915, miR-1207-5p, miR-638
Inflammatory Disease 9.7 × 10−5 miR-1908-5p, miR-320b, miR-638
Inflammatory Response 9.7 × 10−5 miR-1908-5p, miR-320b, miR-638
Renal and Urological Disease 9.7 × 10−5 miR-1908-5p,miR-320b, miR-638
Connective Tissue Disorders 2.8 × 10−3 miR-1207-5p, miR-149-3p
Hematological Disease 2.8 × 10−3 miR-1207-5p, miR-149-3p
Immunological Disease 2.8 × 10−3 miR-1207-5p, miR-149-3p
Cardiovascular Disease 8.5 × 10−3–4.3 × 10−2 miR-320b
Cardiovascular System Development and Function 2.1 × 10−2 miR-320b
Cellular Development 2.1 × 10−2–4.8 × 10−2 miR-320b, mir-467
Cellular Function and Maintenance 2.1 × 10−2 miR-320b
Cellular Growth and Proliferation 2.1 × 10−2–4.8 × 10−2 miR-320b, mir-467
Organismal Development 2.1 × 10−2 miR-320b
Tissue Development 2.1 × 10−2 miR-320b
Gastrointestinal Disease 2.3 × 10−2–4.7 × 10−2 mir-548, miR-320b, mir-550
Cellular Movement 3 × 10−2 miR-320b
Tissue Morphology 4.3 × 10−2 miR-320b
Respiratory Disease 4.7 × 10−2 miR-320b
Respiratory System Development and Function 4.8 × 10−2 mir-467
Table 1.  IPA analysis of significantly represented diseases and functions categories for miRNA commonly 
enriched in ARMS exosomes (Rh30, Rh41). ap-value is indicated as a range for several lower level categories 
within each category.
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RMS-derived exosomes carry specific miRNA relevant to cancer signaling networks. To charac-
terize the cargo of RMS-derived exosomes, we extracted total RNA from both exosomes and their respective cells. 
Consistent with other studies13,16–18, a preponderance of small-sized RNA was detected in RMS exosomes as com-
pared to the respective cell lysates (Fig. 2a). We therefore decided to focus on miRNA content of RMS-derived 
exosomes, using the Affymetrix GeneChip miRNA 3.0 array. Unsupervised hierarchical clustering showed that, 
in ARMS cell lines, exosome miRNA clustered together and separately from cellular miRNA (Fig. 2b, right panel). 
The same was seen for ERMS cell lines JR1 and RD (Fig. 2b, left panel). The Rh36 cell line was the only one where 
exosome and cellular miRNA clustered together reflecting the miRNA content of donor cells (Fig. 2b, left panel), 
and they clustered along with the cellular miRNA of the other ERMS cell lines.
We identified a total of 220 differentially deregulated (either enriched or depleted) miRNA in JR1-derived 
exosomes as compared to cell lysate, 102 in RD-derived exosomes and 22 in Rh36-derived exosomes. JR1- and 
RD-derived exosomes shared 71 deregulated miRNA, whereas 8 miRNA were deregulated in common with 
Rh36-derived exosomes (Fig. 2c). For ARMS cells, we found 317 and 264 differentially deregulated miRNA in 
Rh30- and Rh41-derived exosomes compared to cell lysates, respectively, 155 of which were commonly deregu-
lated in both cell lines (Fig. 2d). There were 31 differentially deregulated miRNA in common among the ERMS 
(JR1 and RD) and ARMS (Rh30 and Rh41) cell lines (Fig. 2e); 7 were also common with Rh36 cell line.
We next focused on enriched miRNA only, since these may be responsible for the observed paracrine-mediated 
effects of RMS cells, as they can be delivered to recipient cells. We found that 34 miRNA were commonly enriched 
in exosomes of the 2 ERMS cell lines JR1 and RD; 2 of these miRNA were also in common with the Rh36 cell line 
(Fig. 2f). In ARMS-derived exosomes, 62 miRNA were commonly enriched in Rh30 and Rh41 exosomes (Fig. 2g). 
Finally, there were 10 miRNA in common among the ERMS (JR1 and RD) and ARMS (Rh30 and Rh41) cell lines, 
and only 2 miRNA (miR-1246 and miR-1268) were commonly enriched in all RMS exosomes including Rh36 
(Fig. 2h). By qRT-PCR analysis, we verified enrichment of 7 out of 9 tested miRNA transcripts, using the noncod-
ing small nuclear U6 RNA for normalization (Fig. 2i). RNAse A treatment of exosome isolates prior to miRNA 
extraction did not alter the level of enrichment of the identified miRNA (Supplementary Fig. S1a). To further 
investigate whether the identified exosomal miRNA were indeed being taken up by recipient cells and are able to 
influence the downstream effects in those cells, we evaluated expression levels of 2 experimentally-proven down-
stream targets of 2 of the identified miRNA: CDK2 (target of miR-63819 which is enriched in ARMS exosomes) 
and CEBPß (target of miR-92b-star20 which is enriched in ERMS exosomes). We found that, as expected, protein 
levels of both were decreased in lysates of recipient cells of these respective exosomes after 48 hours of treatment, 
when compared to control-treated cells (Fig. 2j).
We analyzed the 62 miRNA commonly enriched in exosomes derived from both ARMS cell lines using the 
Ingenuity Pathway Analysis (IPA) software. The highest statistically significant experimentally observed and pre-
dicted diseases and functions were within the category of ‘Cancer’, followed by ‘Organismal Injury’, ‘Reproductive 
System disease’, and ‘Inflammatory Disease’ (Table 1). As for the 34 miRNA commonly enriched in the 2 ERMS 
cell lines JR1 and RD, significantly represented categories included ‘Connective Tissue Disorders’, ‘Inflammatory 
Category p-valuea Identified miRNA
Connective Tissue Disorders 3.6 × 10−4 miR-4270, miR-1275
Hematological Disease 3.6 × 10−4 miR-4270, miR-1275
Immunological Disease 3.6 × 10−4 miR-4270, miR-1275
Inflammatory Disease 4.8 × 10−4 miR-4651, miR-1908-5p
Inflammatory Response 4.8 × 10−4 miR-4651, miR-1908-5p
Organismal Injury and Abnormalities 4.8 × 10−4–2.7 × 10−2 miR-1268, miR-4651, miR-1908-5p, miR-1228-5p
Renal and Urological Disease 4.8 × 10−4 miR-4651, miR-1908-5p
Cancer 8.41 × 10−3–2.7 × 10−2 miR-1268, miR-1275, miR-1228-5p
Reproductive System Disease 2.7 × 10−2 miR-1268
Table 2.  IPA analysis of significantly represented diseases and functions categories for miRNA commonly 
enriched in ERMS exosomes (JR1, RD). ap-value is indicated as a range for several lower level categories within 
each category.
Category p-valuea Identified miRNA
Cancer 9.1 × 10−3 miR-1268
Organismal Injury and Abnormalities 9.1 × 10−3–1.14 × 10−2 miR-1268, miR-1908-5p
Reproductive System Disease 9.1 × 10−3 miR-1268
Inflammatory Disease 1.1 × 10−2 miR-1908-5p
Inflammatory Response 1.1 × 10−2 miR-1908-5p
Renal and Urological Disease 1.1 × 10−2 miR-1908-5p
Table 3.  IPA analysis of significantly represented diseases and functions categories for miRNA commonly 
enriched in 4 RMS cell line exosomes (Rh30, Rh41, JR1, RD). ap-value is indicated as a range for several lower 
level categories within each category.
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Disease’, ‘Organismal Injury’ and ‘Cancer’ (Table 2). For the 10 miRNA common among the 4 cell lines (Rh30, 
Rh41, RD, and JR1), significantly represented categories were predicted to be involved in categories of ‘Cancer’, 
‘Organismal Injury’, ‘Reproductive System’, and ‘Inflammatory disease’, due primarily to 2 of the enriched miRNA 
(Table 3).
Focusing on the 2 miRNA common to exosomes derived from all 5 RMS cell lines (miR-1246 and miR-1268), 
we employed Target Scan software to identify their putative targets. The top PANTHER pathways identified in 
which putative targets were involved included Wnt signaling pathway, GnRH receptor pathway, Inflammation, 
Cadherin and Integrin signaling pathways, Angiogenesis, PDGF, EGF, TGF-beta signaling pathways, along with 
apoptosis, p53 and Ras pathways, among others (Supplementary Table S1).
Finally, IPA network analysis showed that, for miRNA enriched in ERMS-derived exosomes, there were 8 
significantly represented networks, 3 of which included more than one identified focus miRNA, with nodes cen-
tering on proteins implicated in cancer cell cycle biology such as Cyclin D1 (CCND1) (Fig. 3a); IGFBP3, AKT1, 
SP1, HMGA1, NFYB, and YBX1 (Fig. 3b); and CDKN2A (Fig. 3c). In ARMS cells, miRNA commonly enriched 
Figure 3. Network-based analysis of miRNA commonly enriched in ERMS- and ARMS-derived exosomes. 
(a–c) The top three predicted networks in ERMS-derived exosomes and (d–h) the top five predicted networks 
in ARMS-derived exosomes by IPA analysis. Boxes identify miRNA that are commonly enriched in the RMS-
derived exosomes in each network. Edges (lines and arrows between nodes) represent direct (solid lines) and 
indirect (dashed lines) interactions between molecules as supported by information in the Ingenuity knowledge 
base.
www.nature.com/scientificreports/
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in exosomes showed 12 significant networks, 5 of which included more than one identified miRNA, with nodes 
centering on proteins implicated in cancer biology, metastasis, and stemness, such as GSK3b, MDM2, CDKN1A 
(Fig. 3d); PRKACA and MYO1C (Fig. 3e); CASR, CCR2 and BRINP3 (Fig. 3f); CDKN2A, SOX2, YBX1 and 
POU5F1 (Fig. 3g); and CXCL8, IFNAR1, CSF1, and IGF1R (Fig. 3h).
RMS-derived exosomes enhance proliferation of recipient human fibroblasts and recipient 
RMS cells. To test whether exosomes have functional paracrine effects on recipient cells, we then assessed the 
proliferation of normal human BJ fibroblasts as well as RMS cells after treatment with RMS-derived exosomes. For 
these studies, and to identify a possible dose-dependent effect, we used 1X and 10X concentrations of exosomes, 
such that 1X refers to an amount derived from a number of RMS cells equivalent to the number of recipient cells, 
Figure 4. RMS-derived exosomes induce the proliferation of normal fibroblasts and tumor cells. (a) Percent 
viability by MTT assay of normal BJ fibroblasts treated with RMS-derived exosomes (Exo) from the specified 
cell lines, normalized to that of cells treated with control exosome-free media. (b) Percent viability by MTT 
assay of the specified RMS cells treated with their own respective RMS-derived exosomes (Exo), normalized to 
that of cells treated with control exosome-free media. (c) Percent viability by MTT assay of the specified RMS 
cells treated with the specified RMS-derived exosomes (Exo), normalized to that of cells treated with control 
exosome-free media. Cells were treated for 48 and 72 hours (h), as specified. Conditions shown include cells 
treated with exosome-free media (control, white bars), 1X exosomes (grey bars) and 10X exosomes (black bars), 
as specified. Values represent means of at least 3 independent experiments, each performed in triplicate. Bars 
represent standard deviations. Asterisks represent significant p-value < 0.05 compared to control condition.
www.nature.com/scientificreports/
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Figure 5. RMS-derived exosomes induce the migration and invasion of normal BJ fibroblasts and promote 
angiogenesis. Representative photomicrographs for (a) transwell migration assay and (c) matrigel invasion 
assay, of normal BJ fibroblasts after treatment with exosomes from the specified cell lines, at 1X and 10X 
exosome concentration. The control condition is fibroblasts treated with exosome-free (Exo Free) medium.  
(b) and (d) Quantitation of the total number of migrated cells in (a) and invading cells in (c), respectively, at the 
denoted conditions of exosome-free media (control C), 1X and 10X exosome concentrations. (e) Representative 
phase contrast photomicrographs of endothelial tube formation of HUVECs cultured on Matrigel with 1X or 
10X RMS-derived exosomes from the specified cell lines, as well as control (Exo Free medium), as specified. 
Quantitation of the total number of nodes in the conditions shown. Grey bars represent the exosome 1X 
concentration, and black bars the 10X concentration, as specified. All histograms represent the means of at 
www.nature.com/scientificreports/
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while 10X is ten times that amount. Of note, the amount of protein in 1X and 10X concentrations was on average 
0.25 μ g/ml and 2.5 μ g/ml, respectively. These amounts are both within the lower ranges of tumor exosome quan-
tities used in published studies, which seem to range from 0.5 to 40 μ g/ml, when reported6,13.
We used exosomes derived from 2 ERMS cell lines: Rh36 and JR1, and 2 ARMS cell lines: Rh30 and Rh41. 
Treatment of human BJ fibroblasts with exosomes derived from the ERMS or the ARMS cell lines did not increase 
proliferation at the 1X concentration, but an effect became evident after 72 hours at the 10X concentration 
(Fig. 4a). Treatment of each RMS cell line with its own exosomes at the 1X concentration enhanced the prolifer-
ation of the parental cells at 48 hours for all cell lines except Rh36, and at 72 hours for all cells except JR1, while 
treatment with 10X exosomes had a significant effect at both 48 and 72 hours in all cell lines (Fig. 4b). We then 
evaluated whether exosomes derived from ARMS cells would influence proliferation of ERMS cells, and vice versa. 
In all cases, exosome treatment at 10X resulted in an increase in proliferation of the recipient cells by 72 hours, 
and in some cases effects were also seen at 1X concentration and at 48 hours of treatment (Fig. 4c). From the 
above data, we conclude that RMS-derived exosomes can increase the proliferation of recipient fibroblasts, ERMS, 
and ARMS cells, in a seemingly dose-dependent manner. The observed effects on fibroblast proliferation were 
also verified using another human fibroblast cell line, the IMR90 fetal lung fibroblasts (Supplementary Fig. S2a).
RMS-derived exosomes induce migration and invasion of normal fibroblasts, and promote 
angiogenesis. We next investigated the effect of RMS-derived exosomes on invasive and migratory prop-
erties of normal fibroblasts, as tumor-associated fibroblasts have been shown to play a primary role in local 
invasion and metastasis in solid tumors (reviewed in ref. 21). At both 1X and 10X concentrations, treatment 
with ERMS-derived or ARMS-derived exosomes resulted in a clear and significant increase in migration of 
normal BJ fibroblasts, in a seemingly dose-dependent fashion (Fig. 5a,b). Similarly, ERMS- and ARMS-derived 
exosomes both resulted in a significant increase in fibroblast invasion through matrigel at both the 1X and 
10X concentrations, and the effects were more prominent with increased exosome concentration (Fig. 5c,d). 
Similar effects were observed when using a second human fibroblast cell line, the IMR90 fetal lung fibroblasts 
(Supplementary Fig. S2b–e). There was no change in the observed effect on fibroblast migration and invasion 
when exosome isolates were first treated with RNAse A and DNAse (Supplementary Fig. S1b–e).
Next, to investigate the effect of RMS-derived exosomes on angiogenesis, we conducted a matrigel tube for-
mation assay that evaluates the ability of human umbilical vascular endothelial cells (HUVECs) to differentiate 
into capillary-like structures when plated on matrigel22. Addition of RMS-derived exosomes, at both the 1X and 
10X concentrations, resulted in a similar increased cellularity of the network formation compared to cells treated 
with exosome-free medium (Fig. 5e, upper panel). Counting the nodes which are defined as the intersection of 
3 or more branches of tubular connections showed a similar greater than 2-fold increase in the number of inter-
connecting HUVECs when treated with either 1X or 10X RMS-derived exosomes compared to controls (Fig. 5e, 
lower panel). To evaluate the effects of exosomes on cell migration and invasion in vivo, we performed a matrigel 
plug assay, where matrigel plugs were loaded with 100 μ g of Rh30-derived exosomes, or equivalent amount of 
diluent (phosphate-buffered saline), injected subcutaneously into the abdomen of immunosuppressed mice and 
collected 7 days later23,24. We found that exosome-loaded matrigel plugs had significantly increased number of 
infiltrating host cells compared to the control (Fig. 5f), consistent with the results obtained in vitro.
Discussion
Despite multiple attempts at intensifying chemotherapeutic approaches to treatment, limited improvements in 
survival have been made for patients with advanced stage RMS over the past 10 years25. This underlies the need 
to better understand the biology of this tumor in order to identify novel targets for therapy. Since exosomes have 
been shown to be important in mediating metastasis in other types of cancer such as melanoma, breast, and 
pancreatic cancer10,26–28, we hypothesized that they may be also important in RMS-mediated paracrine signaling 
and invasion. We found that RMS cell lines, whether of embryonal or alveolar histologies, secrete quantifiable 
amounts of exosomes. In fact, when we tried to isolate exosomes from normal human fibroblasts (BJ cells) or 
normal human skeletal myoblasts (SkMC cells), the number of exosomes isolated was too low to quantify or 
characterize (negative data not shown). This is in keeping with other studies which suggest that cancer cells may 
secrete higher quantities of exosomes compared to normal cells17,29. Increased levels of exosomes are also detected 
in body fluids of cancer patients when compared to those from healthy controls17, and similar results are noted in 
sera of xenograft-bearing mice29. Notably, all 5 RMS cell lines that we tested were found to secrete similar quanti-
ties of exosomes, as quantified by protein content.
Cancer cell-derived exosomes are implicated in tumor growth, survival, angiogenesis, escape from immune 
surveillance, and stimulating migration and invasion (reviewed in ref. 14). Importantly, tumor-derived exosomes 
have been reported to be both necessary and sufficient for preparing the pre-metastatic niche and support-
ing tumor cell metastasis, by stimulating angiogenesis, modulating stromal cells and remodeling extracellular 
matrix10,26,30, and organotropism of specific metastases was recently found to be dictated by paracrine signaling 
least 3 independent experiments, each performed in triplicate. Bars represent standard deviations. Asterisks 
represent significant p-value < 0.05, compared to control condition. (f) Representative light microscopy 
photomicrographs of H&E stained growth factor–reduced Matrigel plugs containing either PBS (as a vehicle 
control, denoted C) or Rh30-derived exosomes (Exo Rh30), harvested 7 days after subcutaneous injection into 
NOD/SCID mice. Quantitation of the total number of cells within the matrigel plug. Histograms represent 
means for 4 plugs from control ‘C’ PBS-loaded matrigel, and 6 plugs from exosome-loaded matrigel ‘Exo Rh30’. 
Bars represent standard deviations. Asterisks denote p-value < 0.05 compared to control.
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through exosomes27,31. Relatively few studies have evaluated the role of exosomes in paracrine signaling of mes-
enchymal tumors such as sarcomas, or in pediatric cancers. Our study now shows that exosomes derived from 
both ERMS and ARMS cells exert a positive effect on recipient tumor and normal fibroblast cell proliferation. 
Notably, we found that RMS-derived exosomes had a prominent effect on inducing migration and invasion of 
normal human BJ and IMR90 fibroblasts, as well as on stimulating angiogenesis of endothelial cells in culture. 
This shows that both RMS histologies known to be locally invasive can influence non-cancerous supporting cells 
in the microenvironment via exosomes, to facilitate local invasion and possibly metastasis. In vivo, we identified 
a role for RMS-derived exosomes in facilitating host cell infiltration into matrigel plugs, which again supports a 
role in promoting invasion and angiogenesis during RMS tumor progression. As with all exosome isolation tech-
niques, residual amounts of extravesicular protein complexes, RNA, or DNA influencing the observed phenotype 
cannot be completely excluded. Even though exosome treatment with RNAse A and DNAse did not diminish 
the effects on fibroblast cell migration and invasion, this does not completely rule out the possibility of such 
extra-exosomal molecules contributing to the observed results.
The PAX3/7-FOXO1 fusion oncoprotein is thought to be the initiating tumor promoting insult in 
fusion-positive rhabdomyosarcoma. Fusion-negative and fusion-positive RMS are distinct tumor subtypes, 
with different pathways of oncogenic deregulation, and likely divergent cells of origin (reviewed in ref. 1). 
Interestingly, we found that miRNA content of fusion-positive ARMS-derived exosomes clustered together 
even to a higher extent than did the respective cellular miRNA, suggesting common specific paracrine medi-
ators in this highly metastatic RMS subtype. Importantly, most of these miRNA were not shared with the 
fusion-negative ERMS-derived exosomes. Of note, the Rh36 cell line - which is the only ERMS cell line in our 
panel with wild-type p53 - had very few miRNA differentially enriched in exosomes, and this was notably dif-
ferent from the remainder of the examined cell lines. While there is some emerging evidence that p53 may play 
a role in modulating exosome content32,33, whether the p53 status of Rh36 cells contributes to this observation 
is yet unclear and needs to be further investigated. This variance seems to also be consistent with studies in dif-
ferent cell lines and cell types, where some studies showed that the miRNA profile of exosomes reflects that of 
the parent cells34, while other studies found that miRNA can be selectively enriched or depleted from exosomes, 
suggesting that their incorporation into exosomes occurs by a selective sorting mechanism6. Notably, even when 
excluding the Rh36 cell line, we found only 10 miRNA commonly enriched between the ERMS (JR1 and RD) 
and ARMS (Rh30 and Rh41) exosomes, further demonstrating the difference in underlying biology of these 
distinct tumor subtypes.
Several studies have attempted to identify panels of exosome-derived miRNA that can be used as biomarkers 
in different types of cancer17,18. The identified exosome miRNA in our study may therefore be used as a starting 
point, with specific subsets of differentially enriched miRNA as candidate biomarkers of fusion-positive and 
fusion-negative RMS, respectively. However, our study evaluated only miRNA that were significantly enriched in 
exosomes compared to respective cell lysates, since we were primarily interested in miRNA that may have specific 
effects on paracrine signaling and therefore would be expected to be selectively packaged into exosomes. Studies 
to identify biomarkers may need to include miRNA present at relatively high levels in exosomes, irrespective of 
levels present in the respective cells. Such studies would optimally employ RNA sequencing technologies, and 
would be expected to identify a larger number of exosome-expressed miRNA.
Our analysis showed that exosomes derived from the 2 ERMS (fusion-negative) cell lines JR1 and RD, had 
commonly enriched miRNA implicated in cancer-related disease categories such as connective tissue disorders, 
inflammation, and cancer. Significantly represented networks featured proteins previously implicated in ERMS 
biology such as Cyclin D1, IGF, AKT, SP1, and CDKN2A35–39. Network analysis also suggested target proteins 
that, though not previously studied in RMS, have been implicated in other tumor types with roles in cell prolif-
eration such as NFYB40, invasion and metastasis such as YBX141, and cellular transformation such as HMGA142. 
The findings of protein nodes previously implicated in ERMS biology supports the role of exosomes as mediators 
of such pathway alterations, while the findings of novel cancer-associated protein networks opens possibilities for 
investigation of such pathways in ERMS tumors.
As for fusion-positive ARMS cell lines, IPA analysis revealed that commonly enriched exosome miRNA had 
experimentally observed and predicted diseases and functions within the categories of cancer, inflammation, con-
nective tissue diseases, and angiogenesis, all of which suggest a role in tissue invasion. Significantly represented 
networks featured proteins previously implicated in ARMS biology (GSK3b, MDM2, CDKN1A, CDKN2A, 
IGF1R)43–47, proteins involved in immune evasion and tumor metastasis (CXCL8, CSF1, IFNAR1, CCR2, 
CASR)48–52, stemness (SOX2, POU5F1)53,54, tumor cell proliferation and invasion (YBX1)41, or have been associ-
ated with other tumor types with a possible role in tumor biology (PRKACA, MYO1C, BRINP3)55–57. The finding 
of the miRNA networks targeting proteins involved in stemness, immune evasion and metastasis, enriched in 
ARMS but not ERMS exosomes, suggests that paracrine signaling via exosomes may have differential effects on 
mediating the known aggressive behavior of ARMS. Further studies will now focus on validation of these can-
didate proteins in human samples and cell lines, and investigation of validated pathways as therapeutic targets.
Interestingly, there were only 2 miRNA that were commonly enriched among all 5 RMS cell lines, namely 
miR-1246 and miR-1268. The miRNA miR-1246 has been reported as a possible biomarker in esophageal squa-
mous cell carcinoma58, colorectal cancer59 and cervical cancer60, and its antagonism led to suppression of prolif-
eration, colony formation and invasion in non-small cell lung cancer cell lines61. Conversely, very little is known 
regarding the functions of miR-1268, other than that it is expressed in gestational diabetes mellitus62, and may be 
implicated in facioscapulmohumeral muscular dystrophy63. Using the Target Scan software and PANTHER analy-
sis, we identified 4395 putative targets of miR-1246 and miR-1268 combined, with effects on pathways implicated 
in tumorigenesis, such as Wnt, Cadherin, EGF and FGF, angiogenesis, and apoptosis signaling. Interestingly, the 
top 2 pathways identified (namely Wnt and GnRH signaling pathways) were among the top 15 statistically sig-
nificant pathways implicated as targets of miRNA upregulated in exosomes secreted by murine C2C12 myoblasts 
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during differentiation64. This may reflect the importance of deregulation of differentiation pathways during 
tumorigenesis, knowing that RMS cells have an activated myogenic program and likely originate from myo-
blast precursor cells (reviewed in ref. 1). The identification of these common miRNA among both ERMS and 
ARMS-derived exosomes is therefore particularly interesting, as it may offer a common therapeutic target for 
both disease subtypes. Further studies using functional assays to specifically investigate the contribution of these 
identified miRNA to RMS tumor biology are currently underway.
The observed effects of RMS-derived exosomes on cell proliferation, migration, invasion, and angiogenesis 
may be due to multiple exosome components, including miRNA, but also protein, mRNA, and even DNA frag-
ments, all of which have been identified in exosomes of different cell lines and likely contribute to paracrine signa-
ling5. For example, differentially expressed exosome proteins such as integrins can direct their ‘homing’ to specific 
organs to enhance the metastatic process31. Further characterization of RMS exosome protein, mRNA, and other 
molecular content in addition to the miRNA will be needed to better understand the mechanism by which these 
particles exert their physiologic effects, and to identify which of these components are in fact responsible for the 
observed effects on proliferation, migration, invasion, and metastasis.
Methods
Cell culture. The human ERMS cell lines JR1 and Rh36, and the ARMS cell lines Rh30 and Rh41, were gen-
erously donated by Dr. Peter Houghton (Columbus, OH, USA), and have been previously described (reviewed 
in ref. 65). RD (human ERMS), BJ (human foreskin fibroblast), IMR90 (human fetal lung fibroblast), HUVEC 
(human umbilical vein endothelial cells) and HEK293T (human embryonic kidney) cell lines were purchased 
from ATCC (Manassas, VA). Mouse embryonic fibroblasts (MEFs) were isolated from E13.5 embryos of wild type 
mice of a mixed C57BL/6 × 129/Sv 77 genetic background (Jackson Laboratory, Maine). All RMS cells were tested 
and authenticated by DDC Medical (London, UK). Cells were cultured in Dulbecco’s Modified Eagles Medium 
or RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% glutamine, and 1% Pen/Strep (all from 
Sigma), maintained under standard incubator conditions (humidified atmosphere, 95% air, 5% CO2, 37 °C) and 
passaged twice weekly by trypsinization.
Exosome isolation and PKH26 staining. Exosome-free medium was prepared by ultracentrifugation 
of medium supplemented with 20% FBS, at 100,000 × g overnight at 4 °C to effectively deplete exosomes66. 
The resulting supernatant was filtered with 0.22 μ m filter (Millipore), and diluted 1:1 in FBS-free medium to 
reach 10% FBS concentration. Cells were incubated in 150 mm plates in exosome-free medium for 72 hours, 
conditioned media were collected and exosomes isolated by differential centrifugation as per ‘Basic Protocol 1’ 
described by Théry et al.67. The pellet was resuspended directly in PBS for functional assays, in lysis buffer for 
protein extraction, in Trizol® (Invitrogen) for miRNA extraction, or in 200 μ g/ml RNAse A with or without 200 μ 
g/ml DNAse (Roche) for 30 min at 37 °C. For all functional assays, cells were treated with exosomes at 1X and 
10X concentration, where 1X corresponds to the quantity of exosomes isolated from a known number of cells and 
used to treat equivalent number of cells and 10X exosomes corresponds to 10 times the 1X quantity. For PKH26 
(Sigma) staining, exosomes were isolated with the following changes: following the first 100,000 × g centrifuga-
tion, the pellet was resuspended in 500 μ L PKH26 membrane dye-diluent C (Sigma) and incubated for 5 minutes 
at room temperature, along with a control aliquot containing PKH26 membrane dye-diluent C without exosomes. 
The labeling reaction was stopped by adding an equal volume of 1% BSA. Labeled exosomes were ultracentri-
fuged at 100,000 × g for 70 minutes, and the pellet was resuspended in medium.
GFP transduction, confocal and scanning electron microscopy. Retrovirus expressing GFP under 
control of MSCV promoter (MSCV-GFP) was generated using calcium phosphate transfection of HEK293T 
packaging cells (ATCC), then titrated. Virus was then added with 8 μ g/ml Polybrene (hexadimethrine bromide, 
Sigma) to cultured MEFs, followed by spinoculation at 32 °C and 2500 rpm for 2 hours. Medium was replaced 
after 3 hours, and process was repeated the next day. GFP-transduced MEFs were then exposed to PKH26-stained 
exosomes or control diluent for 2 hours. For live-cell imaging, cells were plated on a confocal dish (MatTek corpo-
ration, USA). Images were acquired at 37 °C every 15 minutes for 2 hours, using a Zeiss LSM 710 confocal micro-
scope (Zeiss, Germany) and a 63X objective lens. Z-stacks were acquired every 0.2 μ m for the complete depth of 
the cells. For Scanning Electron Microscopy (SEM), exosome pellets were fixed in 2% paraformaldehyde and 1% 
glutaraldehyde (Sigma). The sample was then applied to a continuous carbon grid, washed 8 times in distilled 
H2O, then dehydrated with graded ethanol steps, left to dry, and observed using a Zeiss SEM at 30 kV. ImageJ 
software (http://rsbweb.nih.gov/ij/) was used to quantify the diameter of the photographed exosomes.
Protein analysis. Cells and exosomes were lysed using CHAPS lysis buffer (30 mM Tris-Cl, pH 7.5; 150 mM 
NaCl; 1% CHAPS) mixed with 25X protease inhibitor (Roche), and sonication. Proteins were quantified by 
Bradford method (Bio-Rad). Electrophoresis was performed using 10% acrylamide gel, proteins were trans-
ferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad) and probed with the following antibodies: 
anti-TSG101 (Abcam), anti-HSC70, anti-GAPDH, anti-Calnexin, anti-C/EBPβ , anti-CDK2 (all from Santa Cruz 
Biotechnology), anti-FOXO-1 (Cell Signaling), and appropriate species-specific HRP-conjugated secondary anti-
bodies (Santa Cruz), and detected using ECL reagent (Roche).
RNA extraction, miRNA profiling and analysis. Total RNA was isolated from exosome samples and 
respective cells using Trizol® (Invitrogen) according to manufacturer’s instructions. RNA concentrations were 
determined by absorption at 260-nm wavelength with an ND-1000 spectrometer (Nanodrop Technologies, 
Wilmington, DE, USA). The Experion electrophoresis system using the standard RNA chips (Bio-Rad) was used 
to assess RNA quality and generate electropherograms. Expression microarrays were performed using Affymetrix 
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GeneChip miRNA 3.0 Arrays kit as described by the manufacturer (Affymetrix, Santa Clara, CA, USA). 
The arrays were washed and stained on the Affymetrix Fluidics station 450, scanned with an Affymetrix gene 
chip scanner 3000 7 G (Affymetrix, Santa Clara, CA, USA) and analysed with the R statistical environment. Data 
normalization was performed using rma algorithm68, annotations were derived using biomaRt69, differential 
expression measured using LIMMA70 and visualization for differentially expressed miRNAs using gplots. We 
used a 1.5-fold change and a false discovery rate (FDR) < 0.05 as the cut-off level. The identified miRNA were 
analysed using Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems, www.ingenuity.com), to identify 
diseases, functions, and networks in which the miRNA identified are implicated. Fisher’s exact test was used to 
assign statistical significance (p < 0.05), and each network’s score was displayed as − log (p value). Target Scan 
version 7.0 (http://www.targetscan.org) was used to predict gene targets of the 2 common deregulated miRNA 
identified, and Panther Software (http://pantherdb.org) was used to identify the biological pathways linked to 
these targets.
Quantitative real-time polymerase chain reaction. The TaqMan miRNA Assays (Applied 
Biosystems) hsa-miR-1246, hsa-miR-4726-5p, hsa-miR-92b-5p, hsa-miR-4689,hsa-miR-4487, hsa-miR-4793-3p, 
hsa-miR-595, has-miR-3148 and hsa-miR-486-3p were used, and the noncoding small nuclear U6 RNA (RNU6) 
was used as endogenous control. Reactions were performed in triplicate in 10 μ l volumes, on at least 3 different 
biologic replicates. Quantitative miRNA data were acquired and analysed using the CFX96 real-time PCR detec-
tion system (Bio-Rad). Ct values > 35 were considered to be below the detection level of the assay. Therefore, only 
the miRNA with a Ct ≤ 35 were included in the analyses. Relative miRNA expression levels were compared via 
the 2− Δ Δ Ct method71.
MTT cell viability assay. Cells were seeded in 96-well plates and cultured as above. The following day, 
medium was replaced by exosome-free medium and treated with exosomes at 1X and 10X concentration, as 
specified. Cells incubated in exosome-free medium were used as a control. MTT cell viability assay (Roche) was 
performed according to the manufacturer’s instructions. Results were computed as the mean percent absorbance 
of exosome-treated condition relative to control (exosome-free condition). Each experiment was repeated at least 
3 times, each performed in triplicate.
Migration, invasion, and tube formation assays. BD Falcon™ Cell Culture Inserts with 8 μ m pore 
size were used for migration assay and the same inserts coated with 10% growth factor reduced Matrigel were 
used for invasion assay (BD Biosciences). Cells were seeded onto the top chamber of a transwell insert in 300 μ l 
exosome-free medium and 600 μ l of serum-free medium was added into the bottom chamber in a 24-well plate. 
Exosomes were added four hours later onto the top chamber, at 2 concentrations as detailed above (1X and 10X). 
Cells incubated in exosome-depleted medium were used as a control. The inserts were fixed after 24–72 hours, 
stained with hematoxylin and eosin (H&E stain), mounted and coverslipped. Slides were air-dried, sealed, pho-
tographed and the migrating/invading cells counted using ImageJ software.
The formation of capillary-like structures was assessed in a 96-well plate using growth factor-reduced Matrigel 
(BD Biosciences). HUVECs (1.5 × 104 cells/well) were plated on top of Matrigel in endothelial basal medium 
containing 1% FBS. Exosomes were added at a concentration of 1X and 10X, and exosome-free medium was used 
as control. Cells were incubated for 2 hours and then evaluated by phase-contrast microscopy and photographed. 
The number of nodes (defined as the intersection of 3 or more branches) formed in each condition was counted 
using the ImageJ software.
Matrigel plug in vivo assay. Animal experiments were conducted in accordance with the American 
University of Beirut Institutional Animal Care and Use Committee guidelines; all animal studies were approved 
by this committee. Six week-old NOD/SCID mice (NOD. CB17-Prkdcscid, Jackson Laboratory) were injected sub-
cutaneously along the abdominal midline with 500 μ L growth factor-reduced Matrigel. Prior to the injection, 
Rh30-derived exosomes (in PBS) corresponding to 100 μ g of protein were added to the Matrigel. An equal volume 
of PBS was used in the Matrigel control. Mice were sacrificed one week later, Matrigel plugs were removed, fixed 
in 4% formaldehyde solution, and embedded in paraffin. Slides were stained with hematoxylin/eosin and photo-
graphed using light microscope, and infiltrating cells were counted using ImageJ Software.
Statistical analysis. Comparisons between experimental groups were performed using Student’s t-test, and 
a p-value below 0.05 was considered as statistically significant. All data is presented as mean ± standard deviation.
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